Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging (LICAS-MR)

  • STATUS
    Recruiting
  • End date
    Jul 7, 2024
  • participants needed
    42
  • sponsor
    Centre Hospitalier Universitaire Dijon
Updated on 7 April 2022
hypertension
glucagon
dyslipidemia
liraglutide
incretins
antidiabetic agents
glucagon-like peptide-1
glucagon-like peptide 1

Summary

Type II diabetes is a known risk factor for heart failure, particularly through the progressive development of diabetic cardiomyopathy. Cardiac metabolic parameters, including myocardial steatosis and epicardial fat, are altered in diabetic patients. The development of new anti-diabetics (incretins) has demonstrated protective cardiovascular effects independent of effects on glycemic control for the first time in the history of these therapies. Thus Glucagon-Like Peptide 1 (GLP-1) agonists improve the recovery of cardiac function after a heart attack and decrease atheromatous processes. It has also been demonstrated in a diabetic rat model that the administration of Liraglutide, a GLP-1 agonist, leads to normalization of myocardial steatosis associated with beneficial cardiac molecular remodeling involving pro-apoptotic, oxidative and metabolic processes. These beneficial cardiovascular effects were observed in the absence of any changes in blood glucose, insulin levels or body weight.

Details
Condition Type II Diabetes
Treatment Liraglutide, Cardiac MRI, Follow up by phone
Clinical Study IdentifierNCT03498001
SponsorCentre Hospitalier Universitaire Dijon
Last Modified on7 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient who has given consent
Adult patient over the age of 50 for men and over 60 for women
Type II diabetes treated without modification of antidiabetic treatment in the previous 3 months
HbA1c ≥ 7.5%
At least one of
treated high blood pressure
obesity (BMI>30 kg/m2)
treated dyslipidemia
Active smoking (from 1 cigarette per day) or quit less than 3 years ago
hereditary coronary heart disease (myocardial infarction or sudden death before the age of 55 in the father/brother, myocardial infarction or sudden death before the age of 65 in the mother/sister)
patient for whom a decision to start add-on treatment with Liraglutide has been made

Exclusion Criteria

Protected adult Patient not affiliated to a national health insurance scheme Pregnant or breastfeeding woman Women who intend to become pregnant or of childbearing age and do not use adequate contraceptive methods
Antidiabetic treatment of the incretin family (GLP-1 agonist or DPP4 inhibitor) Severe
renal failure (clearance <30ml/min according to Cockroft due to gadolinium injection)
Claustrophobia / contraindication to MRI (compatible non-MRI implanted metallic material)
History of hypersensitivity to gadoteric acid or gadolinium-based contrast agents and
meglumine Hypersensitivity to VICTOZA® or any of the excipients History or presence of
pancreatitis (acute or chronic) Chronic inflammatory bowel disease Diabetic gastroparesis
Dysthyroidism
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note